Distribution and Expression of IL-17 and Related Cytokines in Children with &lt;i&gt;Mycoplasma pneumoniae&lt;/i&gt; Pneumonia

Fan, Huifeng; Lu, Bingtai; Yang, Diyuan; Zhang, Dongwei; Shi, Tingting; Liu, Gen

doi:10.7883/yoken.jjid.2019.113

Cited by 18 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Yang et al, miR-155 was poorly expressed but the mRNA expression of TNF-α and IL-6 was upregulated in the bronchoalveolar lavage fluid (BALF) of patients with pneumonia, 17 indicating that miR-155-mediated gene regulation promotes the repolarization of the human alveolar macrophage phenotype and realizes the early transformation of proinflammatory cytokines to antiinflammatory cytokines. In a study by Fan et al, the levels of TNF-α and IL-8 were higher in the BALF than in plasma of children with MPP, and the levels were significantly higher in refractory MPP than in general MPP, 18 indicating that the two cytokines may serve as markers to indicate the pathological changes and severity of pulmonary diseases. In this study, TNF-α and IL-8 were highly According to the multivariate logistic regression analysis, older age, autumn and winter, presence of a low complement state, presence of epidemiological contact history, and long antibiotic treatment duration could increase the risk of MPP in children, especially long antibiotic use time, older age, and the presence of epidemiological contact history.…”

Section: Discussionmentioning

confidence: 96%

Expression of Serum miR-155 in Children with Mycoplasma pneumoniae Pneumonia and Its Role in Immunity to Mycoplasma pneumoniae

Jin¹,

Xue²,

Ruan³

et al. 2021

IDR

View full text Add to dashboard Cite

Objective: To investigate the expression of serum miR-155 in children with Mycoplasma pneumoniae pneumonia (MPP). Methods: A total of 100 children at our hospital with pneumonia caused by Mycoplasma pneumoniae infection were enrolled as a study group, including 45 cases in the acute phase (acute phase group) and 55 in the recovery phase (recovery phase group). An additional 30 healthy children were enrolled during the same period as the control group. The expression levels of miR-155, tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), IL-10, IL-13, immunoglobulin (Ig) G, IgA, complements (C3 and CH50), and T lymphocyte subsets (CD 3

show abstract

Section: Discussionmentioning

confidence: 96%

Expression of Serum miR-155 in Children with Mycoplasma pneumoniae Pneumonia and Its Role in Immunity to Mycoplasma pneumoniae

Jin¹,

Xue²,

Ruan³

et al. 2021

IDR

View full text Add to dashboard Cite

show abstract

“…MPP accounts for 10–40% of all childhood pneumonia [ 8 , 9 ], and it induces the humoral immune response and promotes the synthesis and release of immunoglobulins as well as the formation of immune complexes. Surface antigens of MPP could alter the levels of some cell surface antigens, inducing immune cells, causing them to attack host tissues and cause immune dysfunction [ 10 , 11 ].…”

Section: Discussionmentioning

confidence: 99%

Highly Expressed lncRNA GAS5 in the Serum of Children with Mycoplasma pneumoniae Pneumonia and Its Effect on LAMPs‐Induced Apoptosis and Inflammation

Song

Hong

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

The aim of the study was to explore the serum expression of long noncoding RNA (lncRNA) growth arrest-specific transcript 5 (GAS5) in Mycoplasma pneumoniae pneumonia (MPP) and its effect on lipid-associated membrane proteins (LAMPs)-induced apoptosis and inflammation. Totally, 56 children with MPP (MPP group) and 56 healthy children (NC group) were enrolled. lncRNA GAS5 expression was measured by quantitative real-time polymerase chain reaction (qRT-PCR). Serum levels of tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) were detected using ELISA, and the high mobility family protein B1 (HMGBl) was detected by qRT-PCR. The methylated binding protein 2 (MECP2) was inhibited by gene silencing, and the expression of MECP2, TNF-α, IL-6, HMGBl, p-p65, and p-IκBα was measured. lncRNA GAS5 and TNF-α, IL-6, and HMGBl in the peripheral blood of the MPP group were positively correlated P < 0.05 . The expression of TNF-α, IL-6, HMGBl, and lncRNA GAS5 showed a positive correlation with that of LAMPs. The GAS5-siRNA group showed an increased cell survival rate compared with the scrambled-RNAi group P < 0.05 while showing decreased apoptosis and cell death rates P < 0.05 . In addition, the expression of IL-6, TNF-α, HMGBl, p-p65, and p-IκBα was significantly reduced P < 0.05 . lncRNA GAS5 is highly expressed in the serum of children with MPP and inhibits LAMPs-induced apoptosis and alveolar macrophage inflammation.

show abstract

“…In the process of transforming MPP into RMPP, the monocytes and macrophages secreted large amounts of TNF-α, triggering a series of inflammatory reactions, immune disorders, thereby causing damage to organs. Some studies have demonstrated that TNF-α played an important role in the development of RMPP, which could be used as reference index for the prognosis judgment ( Ding et al, 2018 ; Fan et al, 2019 ; Li et al, 2019a ). As shown in our review, removing heat-phlegm and toxicity therapy had more advantages in shortening antipyretic time, cough disappearance time, lung X-ray infiltrates disappearance time and reducing TNF-α level.…”

Section: Discussionmentioning

confidence: 99%

Chinese Herbal Medicine for the Treatment of Children and Adolescents With Refractory Mycoplasma Pneumoniae Pneumonia: A Systematic Review and a Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Objectives: Chinese herb medicine (CHM) is one of the most popular complementary and alternative therapies, which has been widely used to treat Refractory Mycoplasma Pneumoniae Pneumonia (RMPP). However, the effect and safety of CHM remain controversial. Hence, we conducted this meta-analysis to evaluate whether CHM combination therapy could bring benefits to children and adolescents with RMPP.Methods: Seven databases were used for data searching through November 11, 2020 following the PRISMA checklist generally. Review Manager 5.3, Trial sequential analysis 0.9.5.10 Beta software and Stata16.0 were applied to perform data analyses. Mean difference or risk ratio was adopted to express the results, where a 95% confidence interval (CI) was applied.Results: In general, this research enrolled 17 trials with 1,451 participants. The overall pooled results indicated that CHM was beneficial for children and adolescents with RMPP by improving the clinical efficacy rate [RR = 1.20, 95% CI (1.15, 1.25), p < 0.00001], shortening antipyretic time [MD = −2.60, 95% CI (−3.06, −2.13), p < 0.00001], cough disappearance time [MD = −2.77, 95% CI (−3.12, −2.42), p < 0.00001], lung rale disappearance time [MD = −2.65, 95% CI (−3.15, −2.15), p < 0.00001], lung X-ray infiltrates disappearance time [MD = −2.75, 95% CI (−3.33, −2.17), p < 0.00001], reducing TNF-α level [MD = −5.49, 95% CI (−7.21, −3.77), p < 0.00001]. Moreover, subgroup results suggested that removing heat-phlegm and toxicity therapy had more advantages in shortening antipyretic time, cough disappearance time, lung X-ray infiltrates disappearance time and reducing TNF-α level. Meanwhile promoting blood circulation therapy seemed to be better at relieving lung rale. However, regarding adverse events, the two groups displayed no statistical difference [RR = 0.97, 95% CI (0.60, 1.57), p = 0.91].Conclusion: Despite of the apparently positive results in relieving clinical symptoms, physical signs and reducing inflammation, it is premature to confirm the efficacy of CHM in treating RMPP because of the limitation of quality and the number of the included studies. More large-scale, double-blind, well-designed, randomized controlled trials are needed in future research.

show abstract

Distribution and Expression of IL-17 and Related Cytokines in Children with <i>Mycoplasma pneumoniae</i> Pneumonia

Cited by 18 publications

References 24 publications

Expression of Serum miR-155 in Children with Mycoplasma pneumoniae Pneumonia and Its Role in Immunity to Mycoplasma pneumoniae

Expression of Serum miR-155 in Children with Mycoplasma pneumoniae Pneumonia and Its Role in Immunity to Mycoplasma pneumoniae

Highly Expressed lncRNA GAS5 in the Serum of Children with Mycoplasma pneumoniae Pneumonia and Its Effect on LAMPs‐Induced Apoptosis and Inflammation

Chinese Herbal Medicine for the Treatment of Children and Adolescents With Refractory Mycoplasma Pneumoniae Pneumonia: A Systematic Review and a Meta-Analysis

Contact Info

Product

Resources

About